pros and cons of semaglutide Day 2: Wegovy (Semaglutide 2.4 mg weekly injection) Class: GLP-1 receptor agonist Avg Weight Loss: ~15% baseline weight Dosing: Weekly subcutaneous injection FDA Approved: June 2021 for chronic weight management Is Ozempic Actually The Best
Description
Serious but rare risks (both medications): Pancreatitis Gallbladder disease Acute kidney injury (in severe dehydration cases) Black box warning: Both carry a thyroid C-cell tumor warning based on rodent studies
Combined, these effects can take a heavy toll on an athletes performance
Opportunities extend beyond on-premises dining as well
can be serious if not treated promptly
The primary reason to increase is if weight loss has plateaued or you are not losing weight on tirzepatide at your current dose
